IPSEN PHARMA financials
IPSEN PHARMA
Country: FR Reporting currency: EUR Latest annual report: 2021-12-31
LEI:
96950004ZQHLJ6V8PJ87 Financial statements
(EUR, as reported — unscaled; 119 line items across 2 annual periods)
| Line item | 2021 | 2020 |
|---|---|---|
| Income statement | ||
| Revenue | €3.00B | €2.69B |
| Cost of sales | €538.0M | €490.6M |
| Operating profit (EBIT) | €849.5M | €524.8M |
| Net finance income / (cost) | -€21.3M | -€24.7M |
| Income tax expense | €168.2M | -€17.8M |
| Profit for the year | €646.7M | €548.9M |
| — attributable to owners | €646.6M | €548.0M |
| — attributable to NCI | €100.0K | €900.0K |
| Total comprehensive income | €712.2M | €466.2M |
| Per share | ||
| Basic EPS | €7820.00 | €6610.00 |
| Diluted EPS | €7760.00 | €6570.00 |
| Free cash flow / share | €9757.90 | €8257.68 |
| Cash flow statement | ||
| Net cash from operating activities | €909.2M | €771.3M |
| Net cash from investing activities | -€344.2M | -€163.7M |
| Purchase of PP&E (capex) | €96.0M | €81.4M |
| Purchase of intangibles | €331.7M | €59.3M |
| Net cash from financing activities | -€401.2M | -€307.5M |
| Dividends paid | €83.1M | €83.5M |
| Net change in cash | €163.7M | €300.1M |
| Balance sheet | ||
| Total assets | €5.01B | €4.31B |
| Non-current assets | €3.05B | €2.73B |
| Property, plant & equipment | €647.5M | €646.6M |
| Intangible assets & goodwill | €623.2M | €592.8M |
| Current assets | €1.95B | €1.58B |
| Inventories | €219.4M | €213.9M |
| Trade & other receivables | €564.3M | €476.2M |
| Cash & equivalents | €814.7M | €642.5M |
| Total equity | €2.75B | €2.13B |
| — attributable to owners | €2.75B | €2.13B |
| Non-controlling interests | €2.5M | €2.7M |
| Non-current liabilities | €1.02B | €966.0M |
| Current liabilities | €1.23B | €1.21B |
| Deferred tax liabilities | €101.8M | €79.9M |
| Derived metrics | ||
| Free cash flow | €813.2M | €689.9M |
| Operating margin | 28.3% | 19.5% |
| Net margin | 21.6% | 20.4% |
| Return on equity | 23.5% | 25.7% |
| Cash conversion ratio | 1.41× | 1.41× |
| Capex coverage | 9.47× | 9.48× |
| Other reported items | ||
| Adjustments For Decrease Increase In Inventories | -€500.0K | -€7.1M |
| Adjustments For Decrease Increase In Trade Account Receivable | -€67.3M | €56.3M |
| Adjustments For Deferred Tax Expense | €16.2M | -€136.3M |
| Adjustments For Gains Losses On Change In Fair Value of Derivatives | -€800.0K | €5.0M |
| Adjustments For Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | €9.1M | €153.9M |
| Adjustments For Income Tax Expense | -€32.8M | -€66.9M |
| Adjustments For Increase Decrease In Trade Account Payable | €83.5M | €4.5M |
| Adjustments For Losses Gains On Disposal of Noncurrent Assets | €5.8M | -€5.7M |
| Adjustments For Sharebased Payments | €28.7M | €22.5M |
| Adjustments For Undistributed Profits of Investments Accounted For Using Equity Method | €400.0K | €0 |
| Adjustments For Unrealised Foreign Exchange Losses Gains | €1.1M | €4.6M |
| Bank Overdrafts Classified As Cash Equivalents | €5.5M | €2.8M |
| Basic Earnings Loss Per Share From Continuing Operations | €7820.00 | €6610.00 |
| Basic Earnings Loss Per Share From Discontinued Operations | €0.00 | €0.00 |
| Cash and Cash Equivalents If Different From Statement of Financial Position | €809.1M | €639.6M |
| Cash Flows From Used In Increase Decrease In Current Borrowings | -€310.6M | -€194.9M |
| Cash Flows From Used In Operations Before Changes In Working Capital | €941.4M | €781.4M |
| Comprehensive Income Attributable To Noncontrolling Interests | €300.0K | €1.0M |
| Comprehensive Income Attributable To Owners of Parent | €711.9M | €465.3M |
| Current Provisions | €41.6M | €45.7M |
| Current Tax Assets Current | €122.8M | €83.6M |
| Current Tax Liabilities Current | €10.0M | €10.8M |
| Deferred Tax Assets | €253.1M | €243.2M |
| Diluted Earnings Loss Per Share From Continuing Operations | €7760.00 | €6570.00 |
| Diluted Earnings Loss Per Share From Discontinued Operations | €0.00 | €0.00 |
| Dividends Paid To Equity Holders of Parent Classified As Financing Activities | €82.9M | €83.2M |
| Dividends Paid To Noncontrolling Interests Classified As Financing Activities | €200.0K | €300.0K |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | €5.8M | €500.0K |
| Equity and Liabilities | €5.01B | €4.31B |
| Expense of Restructuring Activities | €19.8M | €45.6M |
| General and Administrative Expense | €199.6M | €187.8M |
| Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | €9.1M | €153.9M |
| Increase Decrease In Working Capital | €32.2M | €10.1M |
| Increase Decrease Through Appropriation of Retained Earnings | €0 | €0 |
| Increase Decrease Through Changes In Ownership Interests In Subsidiaries That Do Not Result In Loss of Control | €0 | — |
| Increase Decrease Through Obtaining Or Losing Control of Subsidiaries Or Other Businesses Liabilities Arising From Financing Activities | -€14.7M | €0 |
| Increase Decrease Through Sharebased Payment Transactions | €34.8M | €22.5M |
| Increase Decrease Through Transfers and Other Changes Equity | -€1.0M | €500.0K |
| Increase Decrease Through Treasury Share Transactions | -€42.8M | -€37.0M |
| Intangible Assets Other Than Goodwill | €1.39B | €1.12B |
| Interest Expense | €23.7M | €27.1M |
| Interest Income On Cash and Cash Equivalents | €2.4M | €2.3M |
| Investment Accounted For Using Equity Method | €26.2M | €19.1M |
| Issued Capital | €83.8M | €83.8M |
| Miscellaneous Other Operating Expense | €172.2M | €127.9M |
| Miscellaneous Other Operating Income | €53.1M | €34.0M |
| Noncurrent Financial Liabilities | €772.2M | €761.6M |
| Noncurrent Investments Other Than Investments Accounted For Using Equity Method | €106.9M | €84.5M |
| Noncurrent Provisions For Employee Benefits | €40.7M | €47.4M |
| Other Adjustments For Noncash Items | -€3.6M | -€36.3M |
| Other Comprehensive Income | €65.5M | -€82.7M |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | €98.8M | -€118.4M |
| Other Comprehensive Income Net of Tax Gains Losses From Investments In Equity Instruments | -€15.8M | €7.3M |
| Other Comprehensive Income Net of Tax Gains Losses On Remeasurements of Defined Benefit Plans | €5.5M | -€1.7M |
| Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net of Tax | €75.8M | -€88.4M |
| Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net of Tax | -€10.2M | €5.7M |
| Other Current Assets | €178.6M | €113.7M |
| Other Current Financial Assets | €54.1M | €48.9M |
| Other Current Financial Liabilities | €174.8M | €408.6M |
| Other Current Liabilities | €401.7M | €250.0M |
| Other Finance Income Cost | -€13.6M | €32.5M |
| Other Inflows Outflows of Cash Classified As Investing Activities | €2.4M | €0 |
| Other Longterm Provisions | €64.0M | €32.0M |
| Other Noncurrent Assets | €4.3M | €3.8M |
| Other Noncurrent Financial Assets | €100.0K | €23.1M |
| Other Noncurrent Nonfinancial Liabilities | €45.8M | €45.1M |
| Other Revenue | €130.2M | €94.5M |
| Proceeds From Disposals of Property Plant and Equipment Intangible Assets Other Than Goodwill Investment Property and Other Noncurrent Assets | €1.1M | €15.0M |
| Proceeds From Issuing Shares | €0 | €0 |
| Proceeds From Noncurrent Borrowings | €30.8M | €11.8M |
| Profit Loss From Continuing Operations | €646.7M | €548.9M |
| Profit Loss From Discontinued Operations | €0 | €0 |
| Purchase of Investments Other Than Investments Accounted For Using Equity Method | €28.4M | €5.9M |
| Repayments of Noncurrent Borrowings | €900.0K | €900.0K |
| Research and Development Expense | €428.4M | €405.6M |
| Reserve of Exchange Differences On Translation | €37.2M | -€59.6M |
| Revenue From Sale of Goods | €2.87B | €2.59B |
| Selling Expense | €835.7M | €784.0M |
| Share of Profit Loss of Associates and Joint Ventures Accounted For Using Equity Method | €400.0K | -€1.5M |
| Trade and Other Current Payables To Trade Suppliers | €594.7M | €495.2M |
Methodology
Every line item above is a fact tagged in IPSEN PHARMA's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.